Moderna, Inc.
905 articles with Moderna, Inc.
-
Moderna has made the official request to the FDA to approve its COVID-19 for use in children ages 6 months to 5 years. Moderna also announced the location of its first non-U.S. mRNA manufacturing facility.
-
Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age
4/28/2022
Moderna, Inc. today announced that it has submitted a request for emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age to the U.S. Food and Drug Administration.
-
Arpa Garay Joins Moderna as Chief Commercial Officer
4/27/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Arpa Garay will join Moderna as Chief Commercial Officer, effective Monday, May 31, 2022.
-
The U.S. Congress is calling for the coronavirus management plan to deliberate on the timeline for the approval and release of vaccines for children under 5 years old.
-
How many boosters are enough to protect against COVID-19 infection? This question has been at the forefront of the minds of everyone as news crops up about yearly boosters.
-
Noubar Afeyan, founder of Flagship Pioneering and Moderna, spoke at an event hosted by the Institute of Global Health Innovation.
-
With COVID-19 still very much a threat to the public, researchers are working on developing new treatments. Read on for more updates.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Although treating patients is the top priority of the biopharma industry, there’s no doubt that money is the driver. This is a broad look at the current state of biopharma bucks.
-
Moderna is poised to seek the regulatory authorization of its COVID-19 vaccine in children between six months and 5 years.
-
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
4/19/2022
Moderna, Inc. today announced new clinical data on its bivalent COVID-19 booster platform including data on the Company's first bivalent booster candidate, mRNA-1273.211.
-
Pharma giant Moderna has shared data on the development of a new bivalent COVID-19 booster vaccine that performs better than its first booster that is currently on the market.
-
Ocugen has amended its co-development, supply and commercialization deal with Bharat to include Mexico and now holds the rights for the Covaxin vaccine for all of North America.
-
Pfizer, J&J and GSK indicate plans to file for regulatory approval by the end of this year for vaccines against RSV, which would see vaccines against the disease becoming available in 2023.
-
Moderna and Thermo Fisher Scientific Honored for COVID-19 Vaccine Efforts
4/14/2022
The PPD clinical research business of Thermo Fisher Scientific and Moderna, whose pioneering mRNA vaccine for COVID has been administered to hundreds of millions globally.
-
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
4/13/2022
Moderna, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results, and provide a corporate update.
-
Moderna tapped Jorge Gomez to take over the role of chief financial officer next month upon the retirement of David Meline, the current company CFO.
-
The FDA is looking at revising the current vaccine strategy and emphasizing that individuals need to consider their own risk tolerance. For that and more, continue reading.
-
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
-
The science community is aware of the effectiveness of the mRNA vaccines developed by Moderna and Pfizer-BioNTech. Now, they may be using that technology to treat cancer.